MYIA
BBIO icon

Mount Yale Investment Advisors’s BridgeBio Pharma BBIO Stock Holding History

Mount Yale Investment Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Buy
+3,271
New +$237K 0.01% 982

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mount Yale Investment Advisors's BBIO Position: Q1 2026 in Review

Mount Yale Investment Advisors opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 3,271 shares worth $243K. The stake represents 0.01% of the portfolio and ranks #982 among its holdings.

458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Mount Yale Investment Advisors held 3,271 shares of BridgeBio Pharma worth $243K as of Q1 2026.
  • BridgeBio Pharma was a new Mount Yale Investment Advisors position in Q1 2026.
  • BridgeBio Pharma made up 0.01% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #982 holding.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.